Gilbertson David, McBean Marshall, Dowd Bryan, Collins Allan
United States Renal Data System Coordinating Center, Minneapolis Medical Research Foundation, Minneapolis, Minnesota 55404, USA.
Am J Med Qual. 2008 May-Jun;23(3):222-30. doi: 10.1177/1062860608314940.
The effect of the diabetes practice guideline recommending >or=2 HbA1c tests annually on diabetes-related outcomes was evaluated using Medicare claims data. The study population included 1998 and 1999 incident diabetes patients aged >or= 67 years, who were Medicare eligible and without known diabetes-related complications at baseline. Number of HbA1c tests was measured 1 year after diabetes incidence. All-cause death and diabetes complications were identified during follow-up, through December 2003. The analysis was conducted with an instrumental variable method and a bivariate probit model, controlling for individual, social, and health care system characteristics. Among 13 033 patients, 27.1% followed the practice guideline. Receiving >or=2 HbA1c tests annually was significantly associated with a decrease in probability of 28.8 percentage points for macrovascular complications, 28.7 for atherosclerotic heart disease, and 23.1 for chronic kidney disease or end-stage renal disease in the 4-year follow-up period.
使用医疗保险理赔数据评估了每年推荐进行≥2次糖化血红蛋白(HbA1c)检测的糖尿病实践指南对糖尿病相关结局的影响。研究人群包括1998年和1999年确诊的年龄≥67岁的糖尿病患者,这些患者符合医疗保险资格且在基线时无已知的糖尿病相关并发症。在糖尿病确诊1年后测量HbA1c检测次数。在随访期间直至2003年12月,确定全因死亡和糖尿病并发症情况。采用工具变量法和双变量概率模型进行分析,同时控制个体、社会和医疗保健系统特征。在13033名患者中,27.1%遵循该实践指南。在4年随访期内,每年接受≥2次HbA1c检测与大血管并发症发生概率降低28.8个百分点、动脉粥样硬化性心脏病降低28.7个百分点、慢性肾脏病或终末期肾病降低23.1个百分点显著相关。